Insys Therapeutics (INSY) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Insys Therapeutics Reports Fourth Quarter and Year End 2015 Results
February 23, 2016 6:50 AM ESTPHOENIX, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December 31, 2015.
Highlights of and subsequent to the fourth quarter of 2015 include:
Total net revenue increased to $91.1 million, compared to $66.5 million for the fourth quarter of 2014; Revenue from Subsys® (fentanyl sublingual spray) was $91.1 million, up 38% compared with fourth quarter 2014 revenue of $66.1 million; Net income was $17.0 million, or $0.24 per basic and $0.22 per diluted share, compared to net... More